| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Molecular Therapeutics [J. L. T., X. F., Y. H., R. L., G. B. M.], Gynecological Oncology [J. K. W.], Biomathematics [E. N. A.], and Experimental Therapeutics [R. A. N., E. A. F.], University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030; Department of Cell and Developmental Biology, University of North Carolina, Chapel Hill, North Carolina [A. J. M., Y. J. S.]; and Department of Obstetrics and Gynecology, The University of British Columbia Vancouver, British Columbia, V6H 3V5, Canada [N. A.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The outcomes of LPA signaling are determined by the spectrum of LPA receptors expressed on the cell surfaces. The LPA1 (Edg 2), LPA2 (Edg 4), and LPA3 (Edg 7) members of the Edg family of G protein-coupled receptors are high affinity receptors for LPA and have been proposed to mediate LPA signaling in mammalian cells (16, 17, 18) . Normal ovarian epithelial cells express low levels of mRNA for LPA2 and LPA3, whereas the mRNA levels for LPA2 and particularly LPA3 are markedly elevated in epithelial ovarian cancers (13 , 19, 20, 21) . LPA1 may exert negative effects on the growth and survival of ovarian cancer cells (19) . In contrast to LPA1 and LPA2, which are activated by LPA with either saturated or unsaturated fatty acyl chains, LPA3 is preferentially activated by LPA with unsaturated fatty acyl chains (18) . LPA has a modest, if any, biological activity on normal ovarian surface epithelium compatible with low-level expression of LPA2 and LPA3 by normal ovarian epithelial cells. Therefore, the high expression of LPA2 and LPA3 in ovarian cancer cells suggests that they have shifted to an LPA-dependent phenotype (13 , 22) .
Lipid phosphate phosphohydrolase-3 (hLPP-3 and PAP2B), a membrane-associated phosphatase, is a widely expressed member of the LPP family, which also includes LPP-1 (PAP2A) and LPP-2 (PAP2C; Ref. 23 ). LPP-like properties serve to terminate the receptor-directed signaling functions of LPA and related compounds (24, 25, 26, 27, 28) . LPPs have been implicated in limiting LPA signaling in multiple systems (28, 29, 30) . LPPs have been proposed to degrade extracellular LPA, particularly that associated with the cell membrane (28) . Indeed, >90% of LPA degradation by ovarian cancer cells is because of the action of LPP-like enzymes (27) . Alternatively, LPPs have been suggested to directly inhibit the function of G protein-coupled receptors of the LPA family (29) , independent of LPA hydrolysis. Intriguingly, the effects of LPPs have under some circumstances been proposed to be independent of the known LPA receptors, implicating additional LPA receptors (30) or LPA receptor-independent effects. Although the LPPs can hydrolyze free phosphates in phospholipids, lysophospholipids, ceramide lipids, and sphingolipids, hLPP-3 shows preference for LPA (31) .
LPA receptors and metabolizing enzymes are altered in expression between normal ovarian epithelium and ovarian cancer cells, suggesting that LPA and its receptors are potential targets for therapy of ovarian cancer. The purpose of this study was to determine the effects of decreasing LPA levels by increasing LPP activity on the pathophysiology of ovarian cancer cells. These studies demonstrated that the introduction of hLPP-3 increased LPA degradation, which was associated with decreased cellular proliferation and increased death in vitro and decreased growth in vivo. The specificity of the effects of hLPP-3 for LPA was demonstrated by studies with the LPP-resistant, LPA3 receptor-specific agonist OMPT and with enzymatically inactive hLPP-3. Taken together, these studies validate LPA metabolism and function as a target for therapy in ovarian cancer.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
G418 Selection.
All of the cell lines were pretested to evaluate G418 (Life Technologies, Inc., Grand Island, NY) resistance. OVCAR-3 and all of the IOSE cell lines were cultured with 400 µg/ml G418, the A 2780 cell line with 500 µg/ml G418, and the SKOV3, SKOV3 IP1, and HEY cell lines with 800 µg/ml G418.
Construction of LPP Vectors.
Four different constructs were assessed. The CMV promoter-driven pcDNA3.1-HisA vector, which adds an in-frame NH2-terminal HisA and V5 epitope tag, and pcDNA3.1-HisA-LacZ constructs were from Invitrogen (Carlsbad, CA). The human hLPP-3 complete cDNA expression vector and an inactive mutant have been described previously (31
, 34
, 35)
. To inactivate hLPP3, the critical histidine in the catalytic domain was mutated to proline (from CAC to CCA at position 561–563 of the cDNA). This has been shown to inactivate hLPP-1 (34)
and to block the activity of hLPP-3 expressed in HEK 293 (data not presented). The complete cDNA of hLPP-3 was amplified using primers with the sequences 5-CGCGGATCCATGCAAAACTACAAGTA-3 (forward) and 5-GCTCTAGACATCATGTTGTGGTGAT-3 (reverse) using PCR. BamHI (site-921 in pcDNA3.1-HisA vector) and XbaI (-983) restriction sides were built into the primer pairs allowing the cDNA to be ligated into the pcDNA3.1-HisA epitope tagged eukaryotic expression vectors. The CMV promoter was deleted, and the hTERT378 promoter was inserted into the pcDNA3.1-HisA expression vector with BglII (-13) and KpnI (-913). The validity of the expression constructs was confirmed by sequencing and restriction endonuclease analyses.
Transient and Stable Expression of hLPP-3.
Cells were plated in 60-mm plastic dishes at a density of 0.5 x 106 cells/dish. At 60% confluent, cells were washed in PBS [(pH 7.4); Sigma, St. Louis, MO]. Cell transfection was carried out using FuGene 6 (Roche Molecular Biochemicals, Indianapolis, IN) according to the manufacturer’s instructions with minor modifications. Briefly, 10 µl of FuGene 6 were added into 100 µl of serum-free medium and incubated 10 min at room temperature. Expression vector (1.5 µg) was added and incubated for 30 min at room temperature. Cotransfection with 0.5 µg of pGFP expressing vector was used to control for transfection efficiency. This mixture was added to 60-mm plate in 3 ml of media. Transiently transfected cells were used 48 h later. Stably transfected SKOV3 and SKOV3 IP1 cell lines were developed by continuous culture in G418. Despite multiple attempts with OVCAR-3, HEY, and A 2780 as well as IOSE 29 and IOSE 80, the ability to generate hLPP-3-expressing stable lines was not successful.
Quantitation of transfection efficiency was done by flow cytometry using a FACScan and Cellquest 3.3 software package (Becton-Dickinson, San Jose, CA). GFP was identified using a single parameter histogram display of log green fluorescence. Cells transfected with an empty vector were used as a negative control to develop a gate to determine the percentage of GFP-positive transfected cells.
Cycle Progression Assay with Transient Transfection.
OVCAR-3 and SKOV3 parental cell lines were transfected with either pcDNA3.1-LacZ-HisA, pchTERT-DNA3.1-HisA, pcDNA3.1-hLPP-3-His A, or pchTERT-DNA3.1-hLPP-3-HisA constructs and cotransfected with pGFP, as described above. Where indicated, pcDNA3-hLPP-3 mutant vectors were assessed to determine the requirement for an intact catalytic activity in hLPP-3. Forty-eight h later, the medium was removed, and the cells were washed twice in PBS and trypsinized. Both floating and adherent cells were harvested and subjected to flow cytometry. Cells were fixed with 0.25% paraformaldehyde (Fisher Scientific, Pittsburgh, PA) in PBS solution followed by addition of propidium iodide (10 µg/ml) for DNA staining. To assess cell cycle progression, a two-color cytometric analysis was performed on a FACScan flow cytometer using Cellquest 3.3 software for acquisition and analysis, as described above. Where indicated, OMPT was added 24 h before assessing cell cycle progression.
Colony Formation Assay.
Two days after transient transfection of the SKOV3 or OVCAR-3 ovarian carcinoma cell lines or the MCF-7 breast carcinoma line, cells were trypsinized, washed in PBS twice, and counted. Cells (3 x 104) were seeded in 30-mm 6 well plates. Stably transfected SKOV3 cells (2 x 103) were seeded into 30-mm 6-well plates. Two weeks later, colonies were stained with 0.1% Coomassie brilliant blue R-250 (Bio-Rad, Hercules, CA) in 30% methanol and 10% acetic acid. Colonies (>500 cells or 1 mm in diameter) were counted by two individuals. Where indicated, 100 nM OMPT were added at the initiation of culture.
LPA Determination in Cell Supernatants.
LPA 18:1 (1 µM) was added to SKOV3 cells and LPP-3-transfected SKOV3 cells, and cell supernatants collected at the indicated times. An unnatural LPA, 17:0, was added to the supernatants after collection to monitor efficiency of isolation and detection of LPA. LPA was extracted from 1 ml of cell supernatant using Waters Oasis HLB 1 cc, 30 mg of solid phase extraction cartridges (Milliford, CT) preconditioned with 1 ml of methanol and 1 ml of water. Cartridges were washed twice with 1 ml of water and dried under vacuum for 5 min. LPA was eluted from the cartridges using 1 ml of 95:5:5 methanol:chloroform:1 M NH4OH. Twenty-five µl of eluant was injected into the LC/MS/MS using a Waters’ XTerra 3.5 µm C18 2 x 100-mm microbore column in a Agilent 1100 binary high-performance liquid chromatography. The column was run in the isocratic mode using a mobile phase of 90:5:5 methanol:chloroform:1 M ammonium hydroxide. LPA isoforms were detected using a MicroMass QuattroUltima triple quadrapole mass spectrometer (Beverly, MA) using electrospray negative ionization with the instrument operating in a multiple reaction-monitoring mode. Specific transitions for each LPA are as follows: LPA 18:1 is 435.24 > 152.8 and LPA 17:0 423 > 152.8. Instrument settings are as follows: cone voltage, 50 V; capillary voltage 3.00 kV; and collision energy 22.
Cell Preparation for Analysis of hLPP-3 Activity.
To assess hLPP-3 activity, stable LPP-3-expressing SKOV3 cells were washed gently with PBS and collected by the addition of 4 ml of ice-cold lysis buffer followed by scraping. The cell suspension was transferred to a 15-ml conical tube, and the cells were disrupted by sonication (Vertis Systems Sonifier), with 10 10-s pulses on ice. The disrupted cells were centrifuged at 20,000 x g at 4 C° for 20 min. The cytosolic fraction was removed, and the membrane fraction was resuspended in ice-cold lysis buffer. Detergent extracts were prepared from the membranes by the addition of 1% of Triton X-100 and 1% of ß-D-octyl glucoside, followed by incubation at 4 C° with constant rocking for 1 h. The solubilized material was centrifuged at 26,000 x g at 4 C° for 30 min, and the supernatant was removed.
Preparation of [32P]LPA.
[32P]LPA was prepared by phosphorylation of Oleoyl monoacylglycerol (monoolein; Avanti Polar Lipids, Alabaster, AL) using Escherichia coli diacylglycerol kinase (Calbiochem, San Diego, CA) and [
32P]ATP (ICN Pharmaceuticals, Costa Mesa, CA). The reaction was terminated by extraction with acidified CHCL3 and methanol, and the dried organic phase obtained was resuspended in 0.4 ml of 20:9:1 CHCL3/methanol/H2O (solvent A) and neutralized by the addition of a small volume of 20% NH4OH in methanol. This material was applied to an Econosil NH2 5 units of high-pressure liquid chromatography column (250 x 4.2 mm; Alltech Associates, Baulkham Hills, NSW, Australia). The column was washed with 20 ml of solvent A and then eluted with a 40-ml linear gradient of 0–1 M ammonium acetate in solvent A. Fractions (0.5 ml) of the eluant were collected, and associated radioactivity was determined by liquid scintillation counting. 32P-labeled products were pooled and extracted from the eluant by the addition of 3 M HCl and CHCL3 to give two phases.
hLPP Enzyme Assays.
The assay procedures used were adapted from those described previously (26)
. In brief, assays were performed in medium containing 20 mM Tris (pH 7.5), 1 mM EGTA, and 2 mM EDTA. 32P-labeled LPA was dried under vacuum and resuspended in 6.4 mM Triton X-100. The assay volume was 100 µl, and each assay contained a final concentration of 3.2 mM Triton X-100 and 100 µM 32P-labeled lipid substrate. Detergent-extracted membrane proteins (generally 0.1–5 µg of protein) were added directly. Assays were performed at 37°C and were terminated by addition of ice-cold 10 mg/ml BSA and 10% trichloroacetic acid. The samples were centrifuged for 5 min in a microcentrifuge, and [32P]PO42- released into the supernatant was quantitated by liquid scintillation counting. This assay was validated by demonstrating that the water-soluble radioactivity released from the substrate was [32P]PO42- by quantitative extraction with ammonium molybdate.
To assess hLPP-3 activity on cell supernatants both parental and stably SKOV3-transfected cells were resuspended in OPTI-MEM medium containing 3% BSA. [32P]LPA was added to a final concentration of 20 µM by bath sonication. Assays were initiated by adding 1 ml of this substrate preparation to 1 ml of cells (4 x 105 cells) followed by incubation at 37°C with constant shaking. Aliquots of the suspension were removed at various times for determination of hLPP-3 activity by measurement of [32P]PO4-2 release as described above.
Analysis of Bystander Effects of hLPP-3.
Two days after transient transfection (see above), OVCAR-3 and SKOV3 cells were trypsinized and counted. Transfected cells (3 x 104) were mixed at different ratios with their respective nontransfected parental cell line and were plated in 6-well plates. Similar approaches were performed with stably transfected SKOV3 cells. Two weeks later, colonies were stained and counted.
Immunoprecipitation and Western Blot Analysis.
SDS-PAGE (12.5% SDS), Western blotting, and protein determinations were performed as previously described (35
, 36)
with the indicated antibodies.
Evaluation of the ERK Activation in LPP-3-transfected Cells.
After 24-h starvation of 90% confluent cell cultures of LPP-3 and neo stably transfected SKOV3 cells, LPA (1 µM) was added and cell lysates prepared at the indicated time points. Western blotting was performed with antiphospho-ERK1/2 (Cell Signaling Technology, Inc., Beverly, MA) and anti-ERK2 antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Relative density of specific bands was determined using NIH Image 1.62.
Semiquantitative RT-PCR of hLPP-3.
The mRNA expression of hLPP-3 was determined using semiquantitative RT-PCR. Oligonucleotide primers were used for: HLPP-3, 5'-CGCGGATCCATGCAAAACTACAAGTA and 5'-CGTGATGATCGCGAGGATGG (306 bp); and GAPDH primers, 5'-CCCATGGCAAATTCCATGGCACCG and 5'-GTCATGGATGACCTTGGCCAGGGG (344 bp).
RNA samples were treated with DNase before the RT-PCR reaction following the manufacturers instructions (DNA-free, DNase Treatment and Removal Kit; Ambion, Austin, TX). The RT-PCR reaction mixtures consisted of cDNA derived from 1 µg of total RNA, 0.4 µM of sense and antisense primers, 0.2 mM of deoxynucleotide triphosphates, 0.5 units of either reverse transcriptase or Taq-DNA polymerase enzymes, 5 mM DTT solution, 5 units of RNase inhibitor, and 1.5 mM MgCl2 in a final volume of 50 µl (Titan One Tube RT-PCR System; Roche Molecular Biochemicals, Mannheim, Germany). The reverse transcriptase reaction was performed at 60°C for 30 min followed by 35 cycles of PCR reaction carried out in a Thermal Cycler (Perkin-Elmer 480, Atlanta, GA). Each cycle of PCR consisted of 30 s of denaturation at 94 C°, 2 min of annealing at 54°C, and 1 min of extension at 72°C. The PCR products were visualized by electrophoresis in a 2% agarose gel with ethidium bromide.
Tumor Growth in Nude Mice.
SKOV3 parental and SKOV3 hLPP-3 or SKOV3 IP1 parental and SKOV3 IP1-hLPP-3 stably transfected ovarian cancer cells (4 x 106 cells) were injected s.c. into the left and right thigh of 6–8 week-old female nude mice (Harlan Laboratories, Ltd., Indianapolis, IN). Tumor sizes (in width and length) were measured, and tumor volumes (mm3) were estimated according to the formula: tumor volume = (long dimension) x (short dimension)2/2 (37)
. On day 50 (SKOV3) or day 26 (SKOV3 IP1), the mice were euthanized, and autopsy was carried out.
I.p. growth was assessed by injection of 1 x 107 cells of SKOV 3 parental and SKOV3 hLPP-3 or SKOV3 IP1 parental and SKOV3 IP1-hLPP-3 cells. Abdominal circumference and body weight were assessed every second day after day 9 (SKOV3 IP1) or day 21 (SKOV3). The mice were euthanized on day 41 (SKOV3) and day 30 (SKOV3 IP1) after injection. At the time of euthanasia, autopsy was performed. Animals with any detectable tumor were counted. Animals free of detectable tumor were excluded from the analysis.
Statistical Analyses.
Unpaired continuous outcomes were compared using Wilcoxon rank sum tests. Paired continuous outcomes were compared using Wilcoxon sign-rank tests. Proportions were compared using 
2 analyses. Longitudinal data were compared using repeated measures of ANOVA. Significance was set at P < 0.05.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
). As shown in Fig. 1B
, the ability of hLPP-3 to decrease colony-forming activity of ovarian cancer cells was dependent on an intact catalytic activity, compatible with the degradation of LPA because transfection of mutant hLPP-3 lacking catalytic activity (34
, 35)
had no effect on colony-forming ability. In contrast to SKOV3 and OVCAR-3 ovarian cancer cell lines, transient expression of hLPP-3 under the control of the CMV promoter only modestly (2-fold, 56% decrease 45 ± 16 to 20 ± 3 colonies) decreased colony-forming activity of the MCF-7 breast cancer cell line. On the basis of observations from our (13)
and other laboratories (39)
that breast cancer cell lines both constitutively and inducibly produce much lower levels of LPA than ovarian cancer cell lines, the MCF-7 breast cancer cell line may not be dependent on LPA for proliferation.
|
. There is selective overexpression of the higher molecular weight species of hLPP-3 in the stable cell line, which corresponds to the mature plasma membrane localized form of the enzyme (35)
.
|
The expression of LPP-3 on the cell surface was confirmed by analysis of the ability of transfected cells to hydrolyze radiolabeled LPA added to the media. As indicated in Fig. 2C
, transfected cells demonstrate increased ability to hydrolyze radiolabeled LPA in the media compared with the parental line (P = 0.03). This was reflected in an increased rate and magnitude of LPA hydrolysis.
The increased ability to hydrolyze radiolabeled LPA translated into a decrease in extracellular LPA. When 1 µM 18:1 LPA was added to media alone, there was no detectable change in LPA concentrations over time (time: 0 min, 780 nM; 10 min, 740 nM; 1 h, 845 nM; and 8 h, 819 nM). In the presence of SKOV3 cells, LPA was hydrolyzed [time: 0 min, 727 nM; 10 min, 580 nM; 1 h, 555 nM; and 8 h, <100 nM (levels > 100 nM were readily detectable in calibration curves)]. Expression of hLPP-3 resulted in a marked decrease in LPA levels (time: 0 min, 808 nM; 10 min, 474 nM; 1 h, 229 nM; and 8 h, <100 nM), particularly at early time points, compatible with increased LPP activity.
As indicated above, expression of hLPP-3 results in increased rates of LPA hydrolysis and LPA concentrations in media. To determine whether this resulted in functional consequences, we assessed the effect of expression of hLPP-3 on LPA-induced phosphorylation of ERKs, a sensitive indicator of LPA signaling. As indicated in Fig. 2, D and E
, expression of hLPP-3 resulted in a decrease in maximal levels of ERK phosphorylation, which was associated with a rapid decrease in ERK phosphorylation levels. At later time points (2–3 h), ERK phosphorylation returned to baseline in both parental and transfected SKOV3 cells, compatible with the decrease in LPA levels to undetectable levels at late times as described above in both cell lines.
hLPP-3 Decreases Growth of Ovarian Cancer Cells through LPA Hydrolysis.
As indicated above, the catalytic activity of hLPP-3 is required for the ability to decrease cell growth and further the expression of hLPP-3 results in a decrease in extracellular LPA levels. To determine whether the effects of hLPP-3 on the growth of ovarian cancer cells was attributable to hydrolysis of extracellular LPA, we assessed the ability of addition of exogenous LPA or a nonhydrolysable LPA analogue, OMPT (40)
, to reverse the effects of hLPP-3 expression. Strikingly, addition of exogenous LPA up to 50 µM failed to reverse the effects of hLPP-3 expression (data not presented). As indicated above, LPA phosphatase activity was increased 4.4-fold by stable expression of hLPP-3, resulting in considerable LPA hydrolytic activity. However, as indicated in Fig. 3, A and B
, OMPT was able to substantially reverse the effects of hLPP-3 on both colony-forming activity and on apoptosis with an OMPT concentration of 100 nM proving optimal in both assays. We assessed whether OMPT could be a competitive inhibitor of hLPP-3 enzyme activity. Although at high concentrations (10 µM), OMPT modestly inhibited hLPP-3 activity, at the concentrations used in this study (10 and 100 nM), OMPT did not alter the ability of hLPP-3 to hydrolyze LPA (data not presented). The ability of exogenous OMPT to reverse the effects of hLPP-3 suggests that the major effect of hLPP-3 on the growth of ovarian cancer cells was because of hydrolysis of extracellular LPA.
|
Strikingly, despite the ability to establish neo-resistant cell lines, we were unable to establish hLPP-3 overexpressing lines in OVCAR-3, HEY, or A2780 ovarian cancer cell lines or in TAg expressing normal ovarian epithelium cells. This failure to establish stable cell lines is compatible with the growth inhibition after transient transfection (Fig. 1A)
. Intriguingly, SKOV3 constitutively produces very high levels of LPA as compared with other ovarian cancer cell lines (13)
, potentially contributing to the ability to tolerate LPP-3.
As indicated in Fig. 1C
, the ability of the stable hLPP-3-expressing SKOV3 cell lines to form colonies was markedly decreased (5.1-fold, 80% decrease) as compared with neo-resistant cells (P = 0.0002). Thus either transient or stable expression of hLPP-3 markedly decreases the ability of ovarian cancer cell lines to form colonies.
hLPP-3 Markedly Increases Apoptosis in Ovarian Cancer Cells.
The decreased ability of ovarian cancer cells to form colonies could either be attributable to decreased cell cycle progression or attributable to increased rates of apoptosis. To assess these possibilities, SKOV3 and OVCAR-3 cells were cotransfected with GFP (to mark transfected cells) and hLPP-3 under either the CMV or hTERT promoters and assessed for cell cycle progression and apoptosis (hypodiploid peak) by staining with propidium iodide. There were no obvious differences in cell cycle progression as indicated by number of cells in G1, S, or G2-M (Fig. 4B)
in control or hLPP-3-expressing SKOV3 or OVCAR-3 cells. However, there was a significant and consistent increase in the hypodiploid peak in hLPP-3-expressing cells (P < 0.0001) compatible with an increased rate of apoptosis (Fig. 4A)
. Thus the decreased ability of hLPP-3-expressing ovarian cancer cells to form colonies is associated with an increased rate of cellular apoptosis. As indicated in Fig. 4B
, a mutant hLPP-3, which is unable to hydrolyze LPA (34
, 35)
, did not alter the apoptosis rate, confirming a need for intact enzyme activity in the effect of hLPP-3 on cell death.
|
We initially determined that the number of colonies formed demonstrated essentially a linear relationship related to the number of cells plated, i.e., there were no effects related to cell crowding at higher concentrations (data not presented). As previously described (Fig. 1, A and B)
, expression of hLPP-3 either transiently or stably resulted in a marked decrease in colony-forming cell activity. To assess the effects of hLPP-3-transfected cells on the growth of nontransfected cells, we combined equal amounts of hLPP-3-expressing cells and parental cells. Thus the expected number of colonies in the combination experiment would be the number of colonies produced by parental cells plus the number of colonies produced by the transfected cells. As indicated in Fig. 5, A and B
, with both transient transfection and with stable cell lines, there was a marked decrease in the number of colonies observed compared with the expected number of the colonies (P = 0.028, P = 0.012). Therefore, hLPP-3-transfected cells were able to decrease the proliferation of parental cells compatible with the effect of hLPP-3 being related to the effects on an extracellular mediator, likely LPA.
|
, the growth rate of both the SKOV3 and SKOV3-IP1 hLPP-3-expressing tumors was markedly decreased as compared with the parental cell lines (note: only mice that developed tumors are used to derive the growth curves; P for both SKOV3 and SKOV3-IP1 < 0.0001, Fig. 6, A and B
). At the termination of the study (mandated by tumor size and American Association of Laboratory Animal Care guidelines), the average SKOV3 parental tumor was 0.48 ± 0.15 g in weight, whereas the hLPP-3-expressing SKOV3 tumors averaged 0.13 ± 0.04 g in weight. Similarly, with the SKOV3 IP1 parental tumor, the average weight was 0.44 ± 0.11 g, whereas hLPP-3-expressing tumors had an average weight of 0.12 ± 0.02 g. Thus with both tumor lines, for the animals that developed tumors, the average tumor weight was four times greater in the parental than in the hLPP-3-expressing tumors.
|
).
As indicated above, hLPP-3 resulted in a marked decrease in take rates and in those cases where tumors formed, a decrease in growth rates. However, after a delay in growth, the hLPP-3-expressing tumors appeared to enter a more rapid growth phase. As the hLPP-3 construct was not under selective pressure in vivo, it was possible that the eventual increase in growth rate was attributable to loss of hLPP-3. As indicated in Fig. 7
, this was indeed the case. After in vivo growth, hLPP-3 levels in the transfected lines were markedly decreased. Even more striking, however, after in vivo growth, hLPP-3 levels were markedly decreased in the parental cell lines. It thus appears that in vivo growth of SKOV3 cells is associated with a down-regulation of expression of both endogenous hLPP-3 and transfected hLPP-3. This suggests that a very strong negative selection exists against hLPP-3 expression in ovarian cancer cells in vivo.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Under normal circumstances, LPA levels in bodily fluids, cell membranes, or cells are low (submicromolar), likely reflecting rapid clearance or degradation of LPA (20) . The major pathway for inactivation of LPA, which is observed in most cell types, including ovarian cancer cells, is dephosphorylation to monoacylglycerol (25 , 27 , 31 , 34) . PAP (PAP-1) was first identified as being involved in glycerolipid synthesis (43) . A second PAP activity (PAP-2) was subsequently characterized in mammalian cells based on a lack of requirement for bivalent cations and insensitivity to inhibition by N-ethylmaleimide (44) . These type 2 enzymes (LPP-1, LPP-2, LPP-3) are widely expressed integral membrane proteins with a pronounced selectivity for LPA (34) . The most likely function of PAP-1 is in lipid synthesis, whereas PAP-2 has an important role in modulating the signaling functions of LPA and phosphatidic acid (27 , 28 , 31 , 45) . hLPP-3 (hPAP-2b) has the highest selectivity for LPA compared with the other isoforms of the hLPP or PAP-2 family (31) .
As demonstrated herein, introduction of hLPP-3 into ovarian cancer cells significantly decreased the ability of ovarian cancer cells to form colonies and to grow both s.c. and i.p. in vivo. The decreased colony-forming cell activity was associated with a marked increase in apoptosis with no obvious differences in cell cycle progression as assessed by flow cytometric analysis.
We were readily able to establish hLPP-3-expressing stable lines on the SKOV3 and SKOV3 IP1 background but not with other ovarian carcinoma cell lines. SKOV3 constitutively produces much higher levels of LPA than the other ovarian carcinoma cell lines (13) , potentially contributing to the ability to form stable hLPP-3-expressing lines on this background. An increase in hLPP-3 in the SKOV3 lines was manifest on semiquantitative RT-PCR, Western blotting, and by an increased ability to hydrolyze LPA. The inability to stably express hLPP-3 in other ovarian cell lines is compatible with a strong negative selection for high-level expression of hLPP-3. This selection appears to be particularly powerful in vivo where the hLPP-3-transfected cells as well as the parental cell lines expressed markedly decreased levels of hLPP-3. This suggests that normal tissue culture in the presence of FCS that contains high levels of LPA as well as precursors for LPA production (13) is permissive for expression of hLPP-3.
The data are most compatible with the hypothesis that hLPP-3 exerts its effects on ovarian cancer cells through decreasing extracellular LPA. Both the ability to decrease colony-forming activity and to induce apoptosis was dependent on an intact catalytic activity suggestive of hydrolysis of a free phosphate in glycerol, sphingosine, or ceramide lipids. The likelihood that the target was LPA was supported by the observation that addition of a nonhydrolysable LPA analogue, OMPT (40) , to the medium substantially reversed the effects of hLPP-3 on both colony-forming activity and cellular apoptosis. Compatible with this contention, LPA levels were decreased in the supernatants of LPP-3-expressing cell lines. Furthermore, signaling downstream of LPA as indicated by phosphorylation of ERKs was curtailed in hLPP-3-expressing cells. HLPP-3 demonstrated a clear bystander effect also consistent with the effects of hLPP-3 being attributable to hydrolysis of an extracellular mediator, likely LPA. This also suggests the potential that hLPP-3 gene therapy could not only alter the growth and survival of transfected or infected cells but also of neighboring cells, resulting in a marked effect on tumor growth. This is compatible with studies indicating that hLPPs can alter cellular growth (28, 29, 30) . It suggests, however, that the activity is because of LPA hydrolysis (28 , 30) rather than an effect on receptor function (29) .
In contrast to the ovarian carcinoma lines, hLPP-3 only modestly (2-fold) decreased the colony-forming ability of the MCF-7 breast cancer cell line. Taken together with the observation that ovarian cancer cell lines constitutively and inducibly produce higher levels of LPA than do breast cancer cell lines (13 , 39) , it is possible that the effects of hLPP-3 on ovarian cancer cells may not be generalizable to other cell lineages. Because of increased expression of LPA receptors (13 , 19 , 20 , 22) , epithelial ovarian cancer cells may be particularly dependent on the activity of LPA and sensitive to therapeutics targeting LPA metabolism or action.
In summary, our results demonstrate that expression of exogenous hLPP-3 causes apoptosis and growth inhibition in ovarian cancer cell lines in vitro and in vivo. The ability of exogenous OMPT to reverse the effect of hLPP-3 in vitro and a requirement for an intact enzyme activity suggest that the major effect of hLPP-3 on the growth of ovarian cancer cells is because of hydrolysis of extracellular LPA. Taken together, the data suggests that LPA production, metabolism, receptor binding, and downstream signaling pathways warrant additional investigation as targets for therapy in ovarian cancer.
|
FOOTNOTES |
|---|
1 The work has been supported by the National Research and Scientific Base Foundation of Hungary Grant OTKA F 29426 (to J. L. T.), the W. M. Keck Center for Cancer Gene Therapy Development Award, University of Texas M. D. Anderson Cancer Center (to J. W., G. B. M., J. L. T.), a development project in SPORE in Ovarian Cancer Grant, University of Texas M. D. Anderson Cancer Center (to J. W., G. B. M., J. L. T.), the M. D. Anderson Cancer Center CCSG Grant P30 CA16672 from the National Cancer Institute, and National Cancer Institute Grant PO1 CA64602 (to G. B. M.). 
2 To whom requests for reprints should be addressed, at University of Texas, M. D. Anderson Cancer Center, Department of Molecular Therapeutics, Box 317, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 745-1134; Fax: (713) 745-1184; E-mail: gmills{at}mail.mdanderson.org
3 The abbreviations used are: LPA, lysophosphatidic acid; Edg, endothelial differentiation gene; LLP, lipid phosphate phosphohydrolase; hLPP, human LLP; PAP, phosphatidic acid phosphatase; hTERT, human telomerase reverse transcriptase; OMPT, 1- Oleoyl-Sn-2-O-Methyl-Rac-Glycero-3-Phosphothionate; CMV, cytomegalovirus; GFP, green fluorescent protein; ERK, extracellular signal-regulated kinase; RT-PCR, reverse transcription-PCR.
Received 5/22/02. Accepted 12/27/02.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. J. Biol. Chem., 272: 3860-3868, 1997.This article has been cited by other articles:
|
|
 |
|
  D. N. Brindley and C. Pilquil Lipid phosphate phosphatases and signaling J. Lipid Res., April 1, 2009; 50(Supplement): S225 - S230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Flanagan, J. M. Funes, S. Henderson, L. Wild, N. Carey, and C. Boshoff Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets Mol. Cancer Ther., January 1, 2009; 8(1): 249 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yu, M. M. Murph, Y. Lu, S. Liu, H. S. Hall, J. Liu, C. Stephens, X. Fang, and G. B. Mills Lysophosphatidic Acid Receptors Determine Tumorigenicity and Aggressiveness of Ovarian Cancer Cells J Natl Cancer Inst, November 19, 2008; 100(22): 1630 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen, A. R. Baydoun, R. Xu, L. Deng, X. Liu, W. Zhu, L. Shi, X. Cong, S. Hu, and X. Chen Lysophosphatidic Acid Protects Mesenchymal Stem Cells Against Hypoxia and Serum Deprivation-Induced Apoptosis Stem Cells, January 1, 2008; 26(1): 135 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bardella, D. Dettori, M. Olivero, N. Coltella, M. Mazzone, and M. F. Di Renzo The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo Clin. Cancer Res., April 1, 2007; 13(7): 2191 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pilquil, J. Dewald, A. Cherney, I. Gorshkova, G. Tigyi, D. English, V. Natarajan, and D. N. Brindley Lipid Phosphate Phosphatase-1 Regulates Lysophosphatidate-induced Fibroblast Migration by Controlling Phospholipase D2-dependent Phosphatidate Generation J. Biol. Chem., December 15, 2006; 281(50): 38418 - 38429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Murph, T. Tanaka, S. Liu, and G. B. Mills Of Spiders and Crabs: The Emergence of Lysophospholipids and Their Metabolic Pathways as Targets for Therapy in Cancer. Clin. Cancer Res., November 15, 2006; 12(22): 6598 - 6602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-q. Wang, Y. Smicun, N. Calluzzo, and D. A. Fishman Inhibition of Matrilysin Expression by Antisense or RNA Interference Decreases Lysophosphatidic Acid-Induced Epithelial Ovarian Cancer Invasion Mol. Cancer Res., November 1, 2006; 4(11): 831 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kai, F. Sakane, Y.-J. Jia, S.-i. Imai, S. Yasuda, and H. Kanoh Lipid Phosphate Phosphatases 1 and 3 Are Localized in Distinct Lipid Rafts J. Biochem., November 1, 2006; 140(5): 677 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Morris, L. M. Schang, and D. N. Brindley Lipid Phosphate Phosphatase-2 Activity Regulates S-phase Entry of the Cell Cycle in Rat2 Fibroblasts J. Biol. Chem., April 7, 2006; 281(14): 9297 - 9306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Springett, L. Bonham, A. Hummer, I. Linkov, D. Misra, C. Ma, G. Pezzoni, S. Di Giovine, J. Singer, H. Kawasaki, et al. Lysophosphatidic Acid Acyltransferase-{beta} Is a Prognostic Marker and Therapeutic Target in Gynecologic Malignancies Cancer Res., October 15, 2005; 65(20): 9415 - 9425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Maghazachi Insights into Seven and Single Transmembrane-Spanning Domain Receptors and Their Signaling Pathways in Human Natural Killer Cells Pharmacol. Rev., September 1, 2005; 57(3): 339 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Braun and R. J. Coffey Lysophosphatidic Acid, a Disintegrin and Metalloprotease-17 and Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Ovarian Cancer: The First Word, Not the Last Clin. Cancer Res., July 1, 2005; 11(13): 4639 - 4643. [Full Text] [PDF]
|
|
|
|
|
|
H. Li, X. Ye, C. Mahanivong, D. Bian, J. Chun, and S. Huang Signaling Mechanisms Responsible for Lysophosphatidic Acid-induced Urokinase Plasminogen Activator Expression in Ovarian Cancer Cells J. Biol. Chem., March 18, 2005; 280(11): 10564 - 10571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Schafer, B. Marg, A. Gschwind, and A. Ullrich Distinct ADAM Metalloproteinases Regulate G Protein-coupled Receptor-induced Cell Proliferation and Survival J. Biol. Chem., November 12, 2004; 279(46): 47929 - 47938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Miyamoto, M. Hirata, A. Yamazaki, T. Kageyama, H. Hasuwa, H. Mizushima, Y. Tanaka, H. Yagi, K. Sonoda, M. Kai, et al. Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer Therapy Cancer Res., August 15, 2004; 64(16): 5720 - 5727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bian, S. Su, C. Mahanivong, R. K. Cheng, Q. Han, Z. K. Pan, P. Sun, and S. Huang Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway Cancer Res., June 15, 2004; 64(12): 4209 - 4217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Fang, S. Yu, R. C. Bast, S. Liu, H.-J. Xu, S.-X. Hu, R. LaPushin, F. X. Claret, B. B. Aggarwal, Y. Lu, et al. Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells J. Biol. Chem., March 5, 2004; 279(10): 9653 - 9661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yamada, K. Sato, M. Komachi, E. Malchinkhuu, M. Tobo, T. Kimura, A. Kuwabara, Y. Yanagita, T. Ikeya, Y. Tanahashi, et al. Lysophosphatidic Acid (LPA) in Malignant Ascites Stimulates Motility of Human Pancreatic Cancer Cells through LPA1 J. Biol. Chem., February 20, 2004; 279(8): 6595 - 6605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-S. Han, C. N. Johnston, and G. M. Carman Vacuole Membrane Topography of the DPP1-encoded Diacylglycerol Pyrophosphate Phosphatase Catalytic Site from Saccharomyces cerevisiae J. Biol. Chem., February 13, 2004; 279(7): 5338 - 5345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Smyth, V. A. Sciorra, Y. J. Sigal, Z. Pamuklar, Z. Wang, Y. Xu, G. D. Prestwich, and A. J. Morris Lipid Phosphate Phosphatases Regulate Lysophosphatidic Acid Production and Signaling in Platelets: STUDIES USING CHEMICAL INHIBITORS OF LIPID PHOSPHATE PHOSPHATASE ACTIVITY J. Biol. Chem., October 31, 2003; 278(44): 43214 - 43223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Luquain, A. Singh, L. Wang, V. Natarajan, and A. J. Morris Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells J. Lipid Res., October 1, 2003; 44(10): 1963 - 1975. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
represents LPP-3-transfected SKOV3, and 
represents the parental SKOV3 cell line. The data represent the mean ± SE from three independent experiments.
